Sign in Subscribe
Biological products industry

Immix Biopharma Announces Class-Leading Safety Profile for CAR-T NXC-201

Strategic Insights

— 1 min read

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, has announced a significant breakthrough in its CAR-T therapy development, NXC-201. The therapy has showcased a class-leading safety profile, including the absence of neurotoxicity of any grade in low-volume disease to-date. This achievement paves the way for potential future indication expansion, solidifying the company's position in the field of cell therapies for serious diseases, including AL Amyloidosis.

Key Takeaways:

  • The CAR-T therapy, NXC-201, has demonstrated a class-leading safety profile, with no reported cases of neurotoxicity in low-volume disease to-date.
  • The treatment is being developed for AL Amyloidosis and other serious diseases, with the company's focus on completing the NEXICART-2 trial for BLA submission.
  • Interim results from the NEXICART-2 trial, including safety data, were presented at the American Society for Clinical Oncology (ASCO 2025) by Heather Landau, MD of Memorial Sloan Kettering Cancer Center.
  • Immix Biopharma is accelerating progress towards completing the NEXICART-2 trial, with a focus on FDA approval.
  • The company believes that NXC-201 has the potential to address a range of immune-mediated and other serious diseases.
  • Gabriel Morris, Chief Financial Officer, stated that the company's near-term efforts are focused on its path to NEXICART-2 BLA submission for FDA approval.
  • Ilya Rachman, M.D., Ph.D., CEO, emphasized the company's singular focus on completing the NEXICART-2 trial and its potential for future indication expansion.

Statistics:

  • The absence of neurotoxicity of any grade in low-volume disease to-date in studies of NXC-201.
  • The NXC-201 therapy has been developed for AL Amyloidosis and other serious diseases.
  • The company is accelerating progress towards completing the NEXICART-2 trial.
  • The NEXICART-2 trial aims to collect safety and efficacy data for BLA submission for FDA approval.
  • The company believes NXC-201 has the potential to address a range of immune-mediated and other serious diseases.

Sources:

  • Immix Biopharma, Inc.'s news release
  • ASCO (2025) presentation by Heather Landau, MD of Memorial Sloan Kettering Cancer Center (ASCO Post article and video, MSKCC article, Cleveland Clinic article)
  • A webcast of the Company's Key Opinion Leader (KOL) event to discuss the NXC-201 ASCO 2025 interim results, including safety results

Read more